Go Back

Messoud Ashina

Messoud Ashina

Institution: Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen
City: Copenhagen
Country: Denmark


Professor Messoud Ashina is Professor of Neurology and Director of the Human Migraine Research Unit at the Department of Neurology & Danish Headache Center, Rigshospitalet, the University of Copenhagen, Denmark. He is Past President of the International Headache Society (2019–2021) and is Past General Secretary of the European Headache Federation. Prof. Ashina is a Fellow of the European Academy of Neurology. In addition, he is an Associate Editor of Cephalalgia, an Associate Editor of The Journal of Headache and Pain, and an Associate Editor of Brain

Prof. Ashina’s research interests include the pathophysiology of migraine and mechanisms of action of antimigraine medications, as well as experimental migraine models, functional neuroimaging, and novel antimigraine drug targets. He has authored over 600 papers, abstracts and book chapters on the topic of headache, including migraine and cluster headache.

Having obtained his MD from the Azerbaijan Medical University, Prof. Ashina went on to complete his residency in neurology at the University of Copenhagen, where he gained his PhD and DMSc. In the past, he has served as President of the Danish Headache Society.


Employment: Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Denmark

Society Leadership/Board: Past President-International Headache Society

Personal fees: AbbVie, Amgen, AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Percept Corporation, Pfizer, Teva

Research support: Lundbeck Foundation, Novo Nordisk Foundation, Novartis, Lundbeck (all to institution)

Data Safety Monitoring Board/Advisory Board: Abbvie, Eli Lilly, Lundbeck, Pfizer, Teva

Clinical trials involvement: Ongoing AbbVie and Pfizer trials

Relationship with scientific journals: Associate editor of Cephalalgia, Associate editor of Journal of Headache and Pain, Associate editor of Brain

Commercial interests: None